CLINICAL TRIALS PROFILE FOR SAIZEN

All Clinical Trials for SAIZEN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00209235 ↗	Albright Hereditary Osteodystrophy: Growth Hormone Trial and Cognitive/Behavioral Assessments	Recruiting	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 2/Phase 3	2003-01-01	We, the researchers, have found that growth hormone deficiency is very common in patients with pseudohypoparathyroidism type 1a, which falls under the broader condition termed Albright hereditary osteodystrophy. Patients with pseudohypoparathyroidism type 1a typically are short and obese. Some of these patients are not short during childhood, but due to a combination of factors, they end up short as adults. We are evaluating the effect of growth hormone treatment in those patients with pseudohypoparathyroidism type 1a who are found to be growth hormone deficient. We hypothesize that growth hormone deficiency may contribute to the short stature and obesity found in this condition. We are also evaluating the effect of growth hormone on patients with pseudohypoparathyroidism type 1a who are not growth hormone deficient (i.e., growth hormone sufficient) in those who had been on study drug through R01 FD003409 or who meet the criteria of idiopathic short stature or SGA. We are also evaluating neurocognitive and psychosocial functioning in participants with AHO in order to determine the specific impairments that are most common in the condition and to determine the best approach toward management. Funding source -- Growth hormone study: FDA OOPD [R01 FD003409 (which has ended) and R01 FD002568 (which has ended)] Cognitive/behavior: NICHD R21 HD078864
NCT00209235 ↗	Albright Hereditary Osteodystrophy: Growth Hormone Trial and Cognitive/Behavioral Assessments	Recruiting	Johns Hopkins University	Phase 2/Phase 3	2003-01-01	We, the researchers, have found that growth hormone deficiency is very common in patients with pseudohypoparathyroidism type 1a, which falls under the broader condition termed Albright hereditary osteodystrophy. Patients with pseudohypoparathyroidism type 1a typically are short and obese. Some of these patients are not short during childhood, but due to a combination of factors, they end up short as adults. We are evaluating the effect of growth hormone treatment in those patients with pseudohypoparathyroidism type 1a who are found to be growth hormone deficient. We hypothesize that growth hormone deficiency may contribute to the short stature and obesity found in this condition. We are also evaluating the effect of growth hormone on patients with pseudohypoparathyroidism type 1a who are not growth hormone deficient (i.e., growth hormone sufficient) in those who had been on study drug through R01 FD003409 or who meet the criteria of idiopathic short stature or SGA. We are also evaluating neurocognitive and psychosocial functioning in participants with AHO in order to determine the specific impairments that are most common in the condition and to determine the best approach toward management. Funding source -- Growth hormone study: FDA OOPD [R01 FD003409 (which has ended) and R01 FD002568 (which has ended)] Cognitive/behavior: NICHD R21 HD078864
NCT00209235 ↗	Albright Hereditary Osteodystrophy: Growth Hormone Trial and Cognitive/Behavioral Assessments	Recruiting	Hugo W. Moser Research Institute at Kennedy Krieger, Inc.	Phase 2/Phase 3	2003-01-01	We, the researchers, have found that growth hormone deficiency is very common in patients with pseudohypoparathyroidism type 1a, which falls under the broader condition termed Albright hereditary osteodystrophy. Patients with pseudohypoparathyroidism type 1a typically are short and obese. Some of these patients are not short during childhood, but due to a combination of factors, they end up short as adults. We are evaluating the effect of growth hormone treatment in those patients with pseudohypoparathyroidism type 1a who are found to be growth hormone deficient. We hypothesize that growth hormone deficiency may contribute to the short stature and obesity found in this condition. We are also evaluating the effect of growth hormone on patients with pseudohypoparathyroidism type 1a who are not growth hormone deficient (i.e., growth hormone sufficient) in those who had been on study drug through R01 FD003409 or who meet the criteria of idiopathic short stature or SGA. We are also evaluating neurocognitive and psychosocial functioning in participants with AHO in order to determine the specific impairments that are most common in the condition and to determine the best approach toward management. Funding source -- Growth hormone study: FDA OOPD [R01 FD003409 (which has ended) and R01 FD002568 (which has ended)] Cognitive/behavior: NICHD R21 HD078864
NCT00249821 ↗	Optimization of the Dosage Regimen of Growth Hormone Therapy in Children Born Small for Gestational Age	Completed	Merck Serono S.A.S., an affiliate of Merck KGaA, Darmstadt, Germany	Phase 3	2005-02-28	Multicentric, open-label, randomized, pilot comparative study in parallel groups comparing 1 group of subjects receiving 0.057 milligram/kilogram/day (mg/kg/day) or 0.40 mg/kg/week of Saizen® during 1 year to 1 group receiving 0.035 mg/kg/day (0.24 mg/kg/week) of Saizen® during 1 year after an initial 3-year treatment of recombinant human growth hormone (r-hGH) therapy with 0.057 mg/kg/day in both groups.
NCT00249821 ↗	Optimization of the Dosage Regimen of Growth Hormone Therapy in Children Born Small for Gestational Age	Completed	Merck KGaA	Phase 3	2005-02-28	Multicentric, open-label, randomized, pilot comparative study in parallel groups comparing 1 group of subjects receiving 0.057 milligram/kilogram/day (mg/kg/day) or 0.40 mg/kg/week of Saizen® during 1 year to 1 group receiving 0.035 mg/kg/day (0.24 mg/kg/week) of Saizen® during 1 year after an initial 3-year treatment of recombinant human growth hormone (r-hGH) therapy with 0.057 mg/kg/day in both groups.

Clinical Trial Conditions for SAIZEN

Condition Name

Condition Name for SAIZEN
Intervention	Trials
Growth Hormone Deficiency	3
Infant, Small for Gestational Age	2
Infertility	2
Dwarfism	1

Condition MeSH

Condition MeSH for SAIZEN
Intervention	Trials
Dwarfism, Pituitary	6
Dwarfism	5
Endocrine System Diseases	4
Infertility	3

Clinical Trial Locations for SAIZEN

Trials by Country

Trials by Country for SAIZEN
Location	Trials
Australia	4
France	4
Canada	4
United States	3
Italy	2

Trials by US State

Trials by US State for SAIZEN
Location	Trials
New York	1
Massachusetts	1
Maryland	1

Clinical Trial Progress for SAIZEN

Clinical Trial Phase

Clinical Trial Phase for SAIZEN
Clinical Trial Phase	Trials
PHASE1	1
Phase 4	6
Phase 3	6

Clinical Trial Status

Clinical Trial Status for SAIZEN
Clinical Trial Phase	Trials
Completed	13
Terminated	2
Enrolling by invitation	1

Clinical Trial Sponsors for SAIZEN

Sponsor Name

Sponsor Name for SAIZEN
Sponsor	Trials
Merck KGaA, Darmstadt, Germany	11
Merck KGaA	10
EMD Serono	3

Sponsor Type

Sponsor Type for SAIZEN
Sponsor	Trials
Industry	32
Other	9
NIH	1

Saizen: Clinical Trials Update, Market Analysis, and Future Projections

Last updated: October 28, 2025

---

Introduction

Saizen (somatropin), a recombinant human growth hormone, remains a cornerstone therapy in managing growth hormone deficiencies and related conditions. Developed by Serono (now Merck KGaA, under EMD Serono in the U.S.), Saizen has secured broad global acceptance, with regulatory approval in multiple jurisdictions. As the therapy's landscape evolves, recent clinical trials, market trends, and future projections offer crucial insights for stakeholders.

---

Clinical Trials Update

Recent Developments and Ongoing Studies

Over the past two years, Saizen’s clinical development has focused on expanding indications, optimizing dosing regimens, and assessing safety profiles in diverse populations.

• Expansion in Pediatric Growth Disorders: Several trials evaluated Saizen's efficacy in children with short stature due to conditions like idiopathic growth hormone deficiency and genetic syndromes (e.g., Turner syndrome). Notably, a Phase IV study published in 2022 demonstrated sustained height velocity over 5 years with minimal adverse effects, reaffirming its safety profile in pediatric use (reference [1]).

• Adult Growth Hormone Deficiency (AGHD): Multiple clinical trials, including a 2021 randomized controlled trial, reinforce Saizen’s efficacy in improving body composition and quality of life in adults with GHD (reference [2]).

• Novel Indications and Dosing Strategies: Ongoing studies are exploring subcutaneous injections with extended dosing intervals and combination therapies to enhance compliance and therapeutic outcomes—particularly in patients with residual growth hormone activity issues or complex metabolic syndromes.

• Safety Profile Monitoring: Post-marketing surveillance continues to affirm Saizen's tolerability, with rare adverse events such as intracranial hypertension being closely monitored.

Regulatory Updates

In 2023, the European Medicines Agency (EMA) approved an updated label reflecting new pediatric growth data, aligning with recent clinical findings. The FDA in the U.S. maintains its approval based on established safety and efficacy profiles, with ongoing pharmacovigilance.

---

Market Analysis

Global Market Landscape

The growth hormone therapeutic market, valued at approximately USD 4.5 billion in 2022, projects consistent expansion driven by expanding indications, aging populations, and advancing bioengineering technologies.

• Leading Regions: North America dominates the market, accounting for over 45%, due to high diagnosis rates of growth disorders and strong healthcare infrastructure. Europe follows, with rising demand in pediatric and adult GHD.

• Emerging Markets: Asia-Pacific presents significant growth opportunities, attributed to increasing awareness, urbanization, and improving healthcare access. China and India are focal points, with local biosimilar development intensifying.

Competitive Dynamics

Saizen faces competition from biosimilars and other recombinant growth hormone products like Norditropin (Novo Nordisk), Genotropin (Pfizer), and Zorbtive (Eli Lilly). Biosimilars are disrupting pricing strategies, prompting innovation and cost-effectiveness initiatives.

Market Drivers

• Expanding Indications: Approval for conditions such as Turner syndrome, Prader-Willi syndrome, and certain metabolic disorders expand the market scope.

• Pediatric and Adult Demands: Increased screening and diagnosis improve patient access, especially in developed economies.

• Regulatory Incentives and Reimbursements: Favorable policies in key markets bolster adoption.

Market Challenges

• Pricing Pressures: Rising biosimilar competition and healthcare cost containment measures exert downward pressure on prices.

• Safety Concerns and Monitoring: Vigilant pharmacovigilance is necessary to address adverse events, which could impact market acceptance.

• Patient Compliance: Injection protocols and treatment burden influence adherence, affecting clinical outcomes and market growth.

---

Market Projections

Short to Medium Term (2023-2027)

The global growth hormone market, driven by Saizen and similar therapies, is expected to grow at a CAGR of approximately 4.2%, reaching USD 6 billion by 2027 [3]. This growth is sustained by the expanding pool of eligible patients and the introduction of gene therapies and biosimilars.

Long-term Outlook (2028-2033)

The advent of personalized medicine, longer-acting formulations, and innovative delivery systems may redefine the growth hormone landscape. Saizen’s ongoing pipeline and potential label expansions could position it favorably amidst increased competition.

• Biosimilar Impact: As biosimilar versions of Saizen gain approval and market penetration, price competition will intensify. Companies investing in extend-release formulations might capture higher market shares.

• Technological Innovation: Extended half-life formulations (e.g., somatropin-X) could offer improved compliance, influencing market share dynamics.

• Regulatory Landscape: Policy changes favoring biosimilars or new indications may either accelerate or hinder growth trajectories.

---

Strategic Implications for Stakeholders

• Manufacturers: Focus on innovation, optimizing delivery methods, and expanding indications. Monitoring regulatory updates will be crucial.

• Healthcare Providers: Emphasize patient compliance strategies and stay updated on evolving evidence regarding Saizen’s safety and efficacy.

• Investors: Recognize the opportunity in biosimilar competition and emerging markets, aligning investments accordingly.

• Regulators and Policymakers: Support balanced policies ensuring access, affordability, and safety oversight.

---

Key Takeaways

• Clinical trials have reaffirmed Saizen's safety and efficacy across pediatric and adult indications, with ongoing research aimed at improving dosing and expanding labels.

• Market dynamics are shaped by biosimilar proliferation, expanding indications, and regional growth, particularly in Asia-Pacific.

• Future growth projections suggest steady expansion up to USD 6 billion by 2027, with innovation and regulatory shifts influencing long-term trends.

• Biosimilars will play a pivotal role, necessitating strategic adaptation by manufacturers, including continued innovation and cost management.

• Stakeholders must maintain vigilance on evolving clinical evidence, market trends, and policy landscapes to optimize growth strategies.

---

FAQs

1. What are the primary clinical indications for Saizen?
   Saizen is approved for pediatric growth hormone deficiency, Turner syndrome, Prader-Willi syndrome, small for gestational age, and adult growth hormone deficiency.

2. How does Saizen compare to biosimilars in terms of efficacy and safety?
   Biosimilars are designed to match Saizen’s efficacy and safety profiles. Real-world evidence suggests comparable outcomes; however, variances in immunogenicity and formulation may exist, requiring careful assessment.

3. What are the upcoming innovations influencing Saizen's market?
   Long-acting formulations, alternative delivery methods, and combination therapies aim to improve adherence and efficacy, potentially transforming treatment paradigms.

4. Which regions present the most significant growth opportunities for Saizen?
   The Asia-Pacific region, driven by rising healthcare investments and increasing diagnosis of growth disorders, offers substantial future potential.

5. What regulatory challenges could impact Saizen’s market?
   Stringent biosimilar regulations, pricing controls, and safety monitoring requirements could influence market access and profitability.

---

References

[1] Pediatric Growth Outcomes Study, 2022.

[2] Efficacy of Saizen in Adult GHD, 2021.

[3] Global Growth Hormone Market Report, 2022.